Delving into the Latest Updates on AviGenics with Synapse

概览

关联

1

项与 AviGenics 相关的药物

SBC-014

靶点

CSF-3R

作用机制

CSF-3R激动剂

在研机构-

原研机构

Alexion Pharmaceuticals, Inc.

在研适应症-

非在研适应症

乳腺癌 [+1]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

1

项与 AviGenics 相关的临床试验

NCT00497809 / Completed临床2期

An Open-Label, Dose Finding, Prospective, Multi Center, Randomized, Parallel Group Study to Assess the Efficacy and Safety of Three Different Dose Levels of AVI 014 (G-CSF) Compared With a Standard Dose of Neupogen® in Breast Cancer Patients at High (>20%) Risk for Chemotherapy Induced Severe Neutropenia

The overall purpose of this study is to assess the dose response, efficacy, and safety of three different dose levels of AVI 014 (granulocyte colony-stimulating factor [G-CSF]) in breast cancer patients at high (>20%) risk for chemotherapy-induced severe neutropenia.

开始日期2007-08-01

申办/合作机构

AviGenics

100 项与 AviGenics 相关的临床结果

登录后查看更多信息

0 项与 AviGenics 相关的专利（医药）

登录后查看更多信息

100 项与 AviGenics 相关的药物交易

登录后查看更多信息

100 项与 AviGenics 相关的转化医学

登录后查看更多信息